VIP and rheumatoid arthritis: Pro-inflammatory mediators released to the joint microenvironment during the disease, such as TNF-α, decrease the expression of VIP, and modulate the VPAC1/VPAC2 ratio, therefore approaching its profile to that of RA-SF [38].